Status:
COMPLETED
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)
Lead Sponsor:
Gruppo Italiano Studio Linfomi
Conditions:
Advanced Hodgkin Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of Hodgkin disease
- Clinical stage IIB, III, IV
- No prior treatment for Hodgkin disease or other malignancy
- Age 18-65 year
- Good cardiac, pulmunar, renal and hepatic function
- Performance status 0-3 (Karnofsky 100- 40)
- Written Informed Consent
Exclusion
- HIV positivity
- Large cell, anaplastic, CD30+ lymphoma
Key Trial Info
Start Date :
April 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
307 Patients enrolled
Trial Details
Trial ID
NCT00443677
Start Date
April 1 2000
End Date
June 1 2007
Last Update
March 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Oncologico Modenese
Modena, Italy, 41100